Difference between revisions of "Selinexor (Xpovio)"
Jump to navigation
Jump to search
m |
m |
||
| Line 14: | Line 14: | ||
*7/3/2019: Granted accelerated approval in combination with dexamethasone for adult patients with relapsed or refractory [[multiple myeloma]] (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. ''(Based on STORM)'' | *7/3/2019: Granted accelerated approval in combination with dexamethasone for adult patients with relapsed or refractory [[multiple myeloma]] (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. ''(Based on STORM)'' | ||
*12/18/2020: Approved in combination with bortezomib and dexamethasone for the treatment of adult patients with [[multiple myeloma]] who have received at least one prior therapy. ''(Based on BOSTON)'' | *12/18/2020: Approved in combination with bortezomib and dexamethasone for the treatment of adult patients with [[multiple myeloma]] who have received at least one prior therapy. ''(Based on BOSTON)'' | ||
| − | + | ==History of changes in EMA indication== | |
| + | *3/26/2021: Initial authorization as Nexpovio | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' KPT-330 | *'''Code name:''' KPT-330 | ||
| − | *'''Brand name:''' Xpovio | + | *'''Brand name:''' Nexpovio, Xpovio |
[[Category:Drugs]] | [[Category:Drugs]] | ||
| Line 29: | Line 30: | ||
[[Category:FDA approved in 2019]] | [[Category:FDA approved in 2019]] | ||
| + | [[Category:EMA approved in 2021]] | ||
Revision as of 13:30, 31 December 2022
Mechanism of action
From NCI Drug Dictionary: An orally available, small molecule inhibitor of CRM1 (chromosome region maintenance 1 protein, exportin 1 or XPO1), with potential antineoplastic activity. Selinexor modifies the essential CRM1-cargo binding residue cysteine-528, thereby irreversibly inactivating CRM1-mediated nuclear export of cargo proteins such as tumor suppressor proteins (TSPs), including p53, p21, BRCA1/2, pRB, FOXO, and other growth regulatory proteins. As a result, this agent, via the approach of selective inhibition of nuclear export (SINE), restores endogenous tumor suppressing processes to selectively eliminate tumor cells while sparing normal cells.
Diseases for which it is used
History of changes in FDA indication
Diffuse large B-cell lymphoma
- 6/22/2020: Granted accelerated approval for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy. (New disease entity; based on SADAL)
Multiple myeloma
- 7/3/2019: Granted accelerated approval in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. (Based on STORM)
- 12/18/2020: Approved in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. (Based on BOSTON)
History of changes in EMA indication
- 3/26/2021: Initial authorization as Nexpovio
Also known as
- Code name: KPT-330
- Brand name: Nexpovio, Xpovio